Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Stock Has Average Target Price of $2.50

Shares of Werewolf Therapeutics, Inc. (NASDAQ:HOWL – Get Free Report) have earned an average recommendation of “Hold” from the six analysts that are presently covering the firm, MarketBeat reports. One analyst has rated the stock with a sell rating, four have assigned a hold rating and one has given a buy rating to the company. The average 12 month target price among analysts that have covered the stock in the last year is $2.50.

Several equities research analysts recently issued reports on HOWL shares. Wall Street Zen upgraded shares of Werewolf Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, August 22nd. Zacks Research cut Werewolf Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Tuesday, November 3rd. Finally, Weiss Ratings downgraded Werewolf Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday.

Read Our Latest Report on Werewolf Therapeutics

Werewolf Therapeutics Price Performance

Shares of HOWL stock opened at $0.94 on Thursday. The stock has a market cap of $45.44 million, a P/E ratio of -1.56 and a beta of 0.55. The company has a fifty day moving average price of $0.99 and a two-hundred day moving average price of $0.71. Werewolf Therapeutics has a one year low of $0.27 and a one year high of $1.20.

Werewolf Therapeutics (NASDAQ:HOWL – Get Free Report) last announced its quarterly earnings data on Friday, November 13th. The company reported ($0.20) EPS for the quarter, beating analysts’ consensus estimates of ($0.22) by $0.02. As a group, equities research analysts anticipate that Werewolf Therapeutics will post -0.89 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in HOWL. Bank of America Corp DE acquired a new stake in Werewolf Therapeutics during the second quarter worth approximately $112,000. Covestor Ltd acquired a new position in shares of Werewolf Therapeutics in the third quarter valued at approximately $124,000. Squarepoint Ops LLC acquired a new position in shares of Werewolf Therapeutics in the second quarter valued at approximately $37,000. BlackRock Inc. acquired a new position in shares of Werewolf Therapeutics in the second quarter valued at approximately $37,000. Finally, Vontobel Holding Ltd. bought a new position in shares of Werewolf Therapeutics during the third quarter worth approximately $55,000. 64.84% of the stock is currently owned by institutional investors.

Werewolf Therapeutics Company Profile

(Get Free Report)

Werewolf Therapeutics, Inc. is a clinical-stage biotechnology company developing medicines for cancer. Its research focuses on cytokines, immune-signaling proteins that can stimulate the body’s immune response against tumors. The company’s INDUKINE platform is designed to keep cytokine therapies inactive until they reach the tumor environment, with the goal of limiting effects on healthy tissue. Its investigational programs include WTX-124, based on interleukin-2, and WTX-330, based on interleukin-12.

Featured Stories

Analyst Recommendations for Werewolf Therapeutics (NASDAQ:HOWL)

Receive News & Ratings for Werewolf Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Werewolf Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.